Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-09-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于科美诊断技术股份有限公司首次公开发行网下配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is issued by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) and concerns the verification opinion on the listing and circulation of restricted shares from the initial public offering (IPO) offline allotment of 科美诊断技术股份有限公司 (Kemei Diagnostic Technology Co., Ltd.). It references regulatory approvals from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange rules. The content details the types of restricted shares, their lock-up periods, shareholder commitments, and the schedule for these shares to become tradable. It includes detailed tables listing shareholders and share quantities. The document is a formal verification opinion related to the IPO share lock-up release and circulation, not a financial report, earnings release, or management discussion. It is not a report publication announcement but a regulatory compliance and verification document. This fits best under Regulatory Filings (RNS), as it is a regulatory compliance announcement and verification opinion regarding share circulation post-IPO, not a financial report or capital change announcement.
2021-09-26 Chinese
科美诊断技术股份有限公司首次公开发行网下配售限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It includes specifics about the number of shares, lock-up periods, shareholder commitments, regulatory approvals, and a comprehensive list of shareholders involved. The document references regulatory approvals from the China Securities Regulatory Commission and compliance with relevant securities laws and stock exchange rules. It does not contain financial statements, earnings data, or management discussion but focuses on the status and release of restricted shares for trading. This type of document is an official announcement related to share capital changes and the unlocking of restricted shares for trading, which fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief report publication announcement or a regulatory filing fallback. Therefore, the classification is SHA with high confidence.
2021-09-26 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司2021年持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2021 Year Continuous Supervision On-Site Inspection Report" by CITIC Securities for Kemei Diagnostic Technology Co., Ltd. It is addressed to the Shanghai Stock Exchange and references regulatory guidelines for continuous supervision of listed companies. The content details the scope and findings of an on-site inspection covering governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, and operational status. It is a detailed regulatory compliance and supervisory report by the sponsor institution, not a financial report like an annual or interim report. The document length is 2731 characters, relatively short, but it contains substantive inspection findings and opinions rather than just an announcement. It is not a certification or a voting result announcement. The nature of the document fits best with an Audit Report / Information (AR) category, as it is a standalone inspection report related to regulatory compliance and internal controls, not a full annual report or earnings release. FY 2021
2021-09-17 Chinese
科美诊断技术股份有限公司关于参加北京辖区上市公司投资者集体接待日的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (541 characters) from the company's board about participating in an investor collective reception day event. It mentions the date and format of the event and invites investors to participate. There is no financial data, no report attached or published, no voting results, no management changes, no earnings or audit information. The document is primarily an announcement about an investor communication event, not a report or detailed presentation. Given the content and length, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2021-09-13 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司2021年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021 Half-Year Continuous Supervision Tracking Report" issued by a sponsoring institution (中信证券股份有限公司) for a listed company (科美诊断技术股份有限公司). It references regulatory frameworks related to securities issuance and listing, continuous supervision, and compliance with Shanghai Stock Exchange rules. The content includes detailed descriptions of supervision activities, risk factors, financial data for the first half of 2021, core competitiveness, R&D progress, use of raised funds, and shareholding information. The document covers a half-year period and contains substantive financial data and analysis, including income, profit, cash flow, and financial ratios. It is not a full annual report but a comprehensive interim report with detailed financial and operational information for a half-year period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-09-06 Chinese
科美诊断技术股份有限公司第一届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board of 科美诊断技术股份有限公司 regarding the review and approval of the company's 2021 semi-annual report and a special report on the use of raised funds. It includes statements ensuring the accuracy and completeness of the semi-annual report and the compliance of the use of funds with regulatory requirements. The document is relatively short (1355 characters) and primarily serves as an official announcement of the Supervisory Board's approval and opinions rather than containing the full semi-annual report or detailed financial data. Therefore, it is not the interim/quarterly report itself but an announcement related to it. Given the nature and length, it fits best under Regulatory Filings (RNS) as a formal compliance announcement rather than a full financial report or a report publication announcement (RPA) which usually states the report is attached or available elsewhere.
2021-08-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.